SCHEDULE: Vanguard Group Reports 4.89% Passive Stake in Corbus Pharmaceuticals

The Vanguard Group has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.89% in Corbus Pharmaceuticals Holdings Inc. common stock as of June 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 599,495 shares of Corbus Pharmaceuticals Holdings Inc. common stock.
• This represents 4.89% of the company's common stock outstanding.
• The filing is an Amendment No. 2 to a previous Schedule 13G.
• The Vanguard Group holds sole dispositive power over 594,800 shares and shared dispositive power over 4,695 shares.
• The Vanguard Group holds no voting power, either sole or shared.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of beneficial ownership by a passive institutional investor. It does not inherently convey positive or negative sentiment about the issuer's performance or future prospects, but rather reflects a standard portfolio holding.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large institutional investor, The Vanguard Group, indicating its passive ownership stake in Corbus Pharmaceuticals Holdings Inc. It reflects a standard portfolio holding rather than a strategic industry move or competitive action.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive institutional holding.
• Company Management: Awareness of a large, passive institutional investor in their shareholder base.

Key Dates

Keywords

Corbus Pharmaceuticals, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Investment Adviser, Passive Investment